A first-in-human phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of the novel fas ligand (FasL) inhibitor M3T01 in adults with advanced solid tumors.

M3T01 - BlueSphere Bio

Keytruda (pembrolizumab) - Merck (MSD)

https://www.asco.org/abstracts-presentations/268119

Rom Leidner; Ashley Drokin; Alex Tran; Grayson DuRaine; Douglas Hanes; William Redmond; Bernard Fox; Alan Korman; Matthew Taylor; Prakash Ambady; Emily Lin; Neda Jooya; Amber Ruiz; Christopher Darus; Cassandra Niemi; Binbin Zheng-Lin; Tara Foote

Apr 21, 2026